Clinical Lymphoma Myeloma and Leukemia This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

SOHO State of the Art Updates and Next Questions | Challenging Cases in Rare T-Cell Lymphomas
Mature T- and NK-cell neoplasms (MTNKN) collectively represent a rare disorder, representing less than 15% of all non-Hodgkin lymphoma (NHL) cases and qualifying for orphan disease designation by the U.S. Food and Drug Administration (FDA). These consist of 9 families in the 5th revised World Health Organization (WHO) classification of lymphoid neoplasms, which are made up of over 30 disease subtypes, underscoring the heterogeneity of clinical features, molecular biology, and genetics across this disease group. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 22, 2023 Category: Hematology Authors: Rahul S. Bhansali, Stefan K. Barta Tags: Review Article Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 19, 2023 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 19, 2023 Category: Hematology Source Type: research

Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies
The Proviral Integration site of Moloney murine leukemia virus (PIM) family of intracellular serine/threonine kinases (PIM1, PIM2, and PIM3) is implicated in the pathogenesis of many hematologic malignancies and solid tumors.1,2 PIM kinases are important downstream effectors of several oncogenic signaling pathways, such as those mediated by Janus kinase/signal transducers and activators of transcription (JAK/STAT), phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT), or nuclear factor-kB.1,3,4 In turn, PIM kinases regulate several key cellular functions including, but not limited to, apoptosis, cell cycle, cell proli...
Source: Clinical Lymphoma, Myeloma and Leukemia - May 15, 2023 Category: Hematology Authors: Manish R. Patel, William Donnellan, Michael Byrne, Adam S. Asch, Amer M. Zeidan, Maria R. Baer, Amir T. Fathi, Andrew T. Kuykendall, Fred Zheng, Chris Walker, Lulu Cheng, Cindy Marando, Michael R. Savona Tags: Original Study Source Type: research

CAR T cell Therapy for Post-Transplant Lymphoproliferative Disorder after Solid Organ Transplantation: A Safe and Feasible Therapy for An Orphan Disease
Post-transplant lymphoproliferative disorder is one of the most common malignancies after solid organ transplant and allogeneic stem cell transplantation. Chimeric antigen receptor T cell therapy has emerged as an effective treatment option for patients with diffuse large B cell lymphoma. Given the concurrent use of immunosuppressive therapy, patients with PTLD were excluded from CAR T cell therapy trials. However, in the relapsed and refractory setting after management with reduction of immunosuppression and standard chemoimmunotherapy, treatment options are limited for PTLD patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 11, 2023 Category: Hematology Authors: Uroosa Ibrahim, Claude Bassil, Julio C Chavez, Farhad Khimani, Michael D Jain, Frederick L Locke, Aleksandr Lazaryan, Keren Osman Tags: Case Report Source Type: research

SOHO State of the Art Updates and Next Questions: Tailoring Upfront Therapy in Mantle Cell Lymphoma
In this article, we will review current strategies for the front-line management of mantle cell lymphoma, an uncommon and biologically and clinically heterogeneous subtype of non-Hodgkin lymphoma that remains incurable with current therapies. Patients invariably relapse with time, and as a result, treatment strategies involve persistent therapy over the course of months to years, including induction, consolidation, and maintenance. Topics discussed include the historical development of various chemoimmunotherapy backbones with continued modifications to maintain and improve efficacy while limiting off-target, off-tumor eff...
Source: Clinical Lymphoma, Myeloma and Leukemia - May 11, 2023 Category: Hematology Authors: Dilan Patel, Brad Kahl Tags: Review Article Source Type: research

Olverembatinib treatment in pediatric patients with relapsed Philadelphia-chromosome-positive acute lymphoblastic leukemia
Historically, children with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) have dismal prognosis despite intensive chemotherapy and additional consolidative hematopoietic cell transplantation for those with poor response to remission induction. In an international study of 610 children with Ph+ ALL treated between 1995 and 2005, complete remission was achieved in 89% of the patients with 7-year event-free survival and overall survival rates of only 32.0% and 44.9%, respectively. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 10, 2023 Category: Hematology Authors: Xiaolan Li, Jingliao Zhang, Fang Liu, Tianfeng Liu, Ranran Zhang, Yumei Chen, Ye Guo, Yongjun Fang, Xiaojun Xu, Ching-Hon Pui, Xiaofan Zhu Tags: Original Study Source Type: research

Comparison of Inpatient Outcomes Between HIV Positive and Negative Hospitalizations for Autologous Stem Cell Transplant Treatment among Lymphoid Malignancies
In this study we looked for differences in adverse hospital outcomes between those with and without HIV among hospitalizations for autologous stem cell transplantations (ASCTs) for lymphoid malignancies. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 9, 2023 Category: Hematology Authors: Marco Ruiz, Muni Rubens, Venkataraghavan Ramamoorthy, Carlo Briones Chavez, Anshul Saxena Tags: Original Study Source Type: research

Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies
Melphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone demonstrated superior progression-free survival (PFS) but directionally different overall survival (OS) favoring pomalidomide (hazard ratio [HR], 1.10) in OCEAN. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 6, 2023 Category: Hematology Authors: Pieter Sonneveld, Paul G. Richardson, Heinz Ludwig, Meletios-Athanasios Dimopoulos, Fredrik H. Schjesvold, Roman H ájek, Haifaa Abdulhaq, Marcus Thuresson, Stefan Norin, Nicolaas A. Bakker, Maria-Victoria Mateos Tags: Original Study Source Type: research

Culturally Responsive Care Delivery in Oncology: The Example of Multiple Myeloma
Multiple myeloma (MM) represents ∼1% of all cancers and is the second most common hematologic malignancy worldwide. The incidence of MM is at least two times higher in Blacks/African Americans compared with their White counterparts, and Hispanics/Latinxs are among the youngest patients diagnosed with the disease. Recent advances in available treatments for MM have demonstrated significant improvement in survival outcomes; however, patients from non-White racial/ethnic groups clinically benefit less due to multiple factors including access to care, socioeconomic status, medical mistrust, underutilization of novel therapie...
Source: Clinical Lymphoma, Myeloma and Leukemia - May 6, 2023 Category: Hematology Authors: Brandon Blue, Amy Pierre, Joseph Mikhael Tags: Review Article Source Type: research

Characterizing Outcomes in Visceral Cutaneous T-Cell Lymphoma: A Single Center Retrospective Study
: Visceral involvement of cutaneous T-cell lymphoma (vCTCL) is a rare but poorly studied complication of CTCL. We aimed to assess clinical characteristics, treatment, and outcomes, associated with vCTCL at our institution. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2023 Category: Hematology Authors: Tony Zibo Zhuang, Ashley McCook-Veal, Jeffrey Switchenko, Tim Niyogusaba, Erica S. Tarabadkar, Katelin Baird, Colin O'Leary, Darina Paulino, Mary Jo Lechowicz, Pamela B. Allen Source Type: research

Heart Failure Among Patients with Multiple Myeloma Treated with Carfilzomib-Based Versus Non –Carfilzomib-Based Regimens in the United States by Race
Carfilzomib treatment for multiple myeloma (MM) can increase heart failure risk. Whether this risk differs by race is unknown. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 27, 2023 Category: Hematology Authors: Shuling Li, Brandon T. Suehs, Alan Fu, Laura Sangar é, Chris Kim, Victor M. Gastanaga, Jiannong Liu, Heng Yan, Yihua Xu, Joseph Mikhael Tags: Original Study Source Type: research

A History and Current Understanding of Acute Erythroid Leukemia
Acute erythroid leukemia (AEL) is a highly aggressive subtype of acute myeloid leukemia. Since the first recognition of an erythroid-predominant hematologic malignancy in the early 20th century, AEL has gone through a turnstile of changing definitions and nomenclature, including eritoleucemia, erythremic myelosis, AML-M6 and pure erythroid leukemia. Ever-changing diagnostic criteria and under recognition have stifled our understanding of, and therapeutic options for, this rare erythroid-predominant myeloid neoplasm. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 27, 2023 Category: Hematology Authors: Coltoff Alexander Tags: Review Article Source Type: research

Risk and Severity of COVID-19 Infection in Monoclonal Gammopathy of Undetermined Significance: A 3-Year Propensity Matched Cohort Study
Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant disorder causing monoclonal plasma cell proliferation in bone marrow. This population is at risk of developing multiple myeloma (MM) and severe viral infections; risk factors of severe COVID-19 infection. Using TriNetX, a global platform providing data of 120 million patients, we aimed to quantify the risk and severity of COVID-19 in MGUS patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 27, 2023 Category: Hematology Authors: Omer S Ashruf, Zara Orozco, David C Kaelber Tags: Original Study Source Type: research

POEMS Syndrome —Clinical Picture and Management. Current Knowledge
POEMS syndrome is a rare form of plasma cell dyscrasia. Difficulties arise already at the stage of making the diagnosis (complex and heterogeneous clinical picture) and continue during the course of treatment (lack of guidelines for therapy, data coming mainly from reports and short series of patients). In this article we review the current state of knowledge on POEMS syndrome diagnostics, clinical characteristics, prognosis, reported treatment outcomes and the emergence of the new therapeutic strategies. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 26, 2023 Category: Hematology Authors: Artur Jurczyszyn, Magdalena Olszewska-Szopa, David Vesole Tags: Review Article Source Type: research